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Practice points
 Squamous cell lung cancer (SqCLC) is challenging to treat according to patients and disease characteristics.
 SqCLC is strongly associated to smoking habit and this increases the stigma toward patients affected by this
disease.
 Immunotherapy has changed the treatment of squamous cell cancer after many years with no relevant changes.
 Despite the identification of specific molecular alterations, progress in targeting oncogenic drivers still runs
behind adenocarcinoma.
 There are not enough resources exclusively dedicated to patients with SqCLC.
Lungcancer is the leading cause of cancer-related deaths in worldwide, and NSCLC represents around
85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the second most common subtype and it
is challenging to treat. New options have been discovered but progresses are still limited for the lack of
‘druggable’ mutations. Specific resources for SqCLC are limited and this condition affects treatment and
outcomes. This paper describes available and emerging therapeutic options and resources that may help
patients to face their disease. We have also performed a monocentric survey collecting information about
smoking habit and sense of guilty and analyzed the possibility for patients to find helpful sources for their
disease. The results suggest that more materials focused on SqCLC are still needed.
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Background
Lung cancer is the leading cause of cancer death worldwide [1] and NSCLC accounts approximately 80–85% of
cases, with the largest part of patients diagnosed in advanced stage of disease. In this setting, the treatment has
a palliative intent aiming to control symptoms and prolong survival [2]. Squamous cell lung cancer (SqCLC) is
the second most common subtype of NSCLC, representing approximately a third of all cases; it is a challenging
subtype of cancer to treat as a result of concomitant-specific patient and disease characteristics, including older age
that may limit chemotherapy use [3], advanced disease at diagnosis and a higher incidence of comorbidities (chronic
obstructive pulmonary disease, cardiovascular disease and diabetes) with poor performance status (PS), that overall
makes treatment decisions more complex compared with non-SqCLC. The vast majority of patients with SqCLC
are current or former heavy smokers, in contrast, adenocarcinoma is more frequent in former, light or never smokers.
The strong association between this disease and smoking contributes to increase negative feelings as stigma, shame,
guilt and in turn, the illness burden [4]. Several clinical studies showed that shame and guilt negatively influence
patient’s lives. Berterö et al. showed that thoughts of death, shame and guilt reduce quality of life and these feelings
led patients to taste a sense of social anguish, with a significant impact on interpersonal interactions [5]. Even after a
diagnosis of lung cancer, clinicians should encourage smoking cessation in order to improve pulmonary function,
radio-chemotherapy outcomes, response to chemotherapy, efficacy of targeted therapy, quality of life and reduce
surgical complications, cancer-related and noncancer-related mortality, cancer recurrence, treatment toxicity, risk of
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developing second primary cancer (mainly for early stages) and risk of noncancer-related comorbidity [6]. A recent
survey of Cancer National Institute found that only 62% of cancer centers routinely provide tobacco educational
materials and 20% do not provide tobacco cessation services [7]. In 2017, Capelletto et al. published an Italian
multicenter survey that investigated the level of smoking cessation counseling offered to patients by healthcare
professionals [8]. From January 2013 to February 2016, 490 patients were evaluated with an anonymous survey
developed by Women Against Lung Cancer in Europe (WALCE), a nonprofit organization. The results showed
that the majority of patients enrolled (76%) stopped smoking after the diagnosis of a respiratory disease, 17%
smoked less and 7% continued smoking. 38% of patients reported to have never received any smoking cessation
counseling. Almost 73% reported a positive judgment about the quality of healthcare’s intervention, but 83% of
patients have stopped smoking overnight without any help. In conclusion, considering all the smoking-related side
effects, greater efforts should be made in order to better support patients in smoking cessation.
Tumor biology & clinical presentation
According to the location of the primary site, SqCLC is classified into central (cSqCLC) and peripheral type
SqCLC [9]. There have been few debates whether the location of SqCLC may increase any difference in biological
features. Recently, a molecular classification of SqCLC, based on gene expression, has been proposed. Patients
with SqCLC have been classified into four categories with different survival outcomes and biological behavior: the
classical (37%), the basal (21%), the secretory (26%) and the primitive (16%) [10]. Genes related to smoking were
overexpressed in classical subtype, genes related to cell adhesion in basal, the secretory subtype was associated with
immune signature and the last one with genes involved in proliferation and DNA repair. Traditionally in literature,
the cSqCLC has been reported to be the most common type accounting for nearly two-third of cases but it has been
noted a trend toward an increase in the occurrence of peripheral type SqCLC. The cSqCLC is centrally located
involving the main airways responsible for symptoms and signs such as cough, dyspnea, atelectasis, obstructive
pneumonia and hemoptysis. Central tumor necrosis with or without cavitation remains a common radiological
finding and SqCLC is still the most common histotype associated with Pancoast syndrome. This syndrome is
clinically characterized by severe shoulder pain, weakness and muscle atrophy of the intrinsic muscles of the hand,
Claude–Bernard–Horner syndrome (ptosis, miosis, enophthalmos and anhidrosis of the ipsilateral side of face)
and upper arm oedema [11]. The standard treatment for this condition has become the combination of induction
chemo-radiotherapy followed by surgery [12]. In the last 15 years, therapeutic advances for patients with metastatic
NSCLC have been substantially limited to adenocarcinoma, while the treatment of SqCLC remained unchanged.
For instance, the discovery of activated mutations in the EGFR, as well as translocation of anaplastic lymphoma
kinase, and the introduction of maintenance treatment have changed the treatment of patients with nonsquamous
carcinoma. This resulted in a tremendous disparity in the way patients with advanced NSCLC were treated, also
considering that outcomes associated with conventional therapies remain poor. However, recent efforts to define the
biology of SqCLC, together with the introduction of immunotherapy agents, have begun to change the landscape,
including characterization of previously unknown genomic, signaling pathways and delineation of new potentially
actionable molecular targets [13]. These alterations often do not appear to be mutually exclusive (in contrast to
what frequently described in adenocarcinoma). This will likely complicate the interpretation of efficacy data of
treatments directed against single targets.
In this article we are describing treatment’s algorithm and future therapeutic strategies for advanced SqCLC
and we are assessing the availability of materials that could help patients to increase the treatment adherence and
face the disease. With this purpose, we have also performed a monocentric survey to identify and to compare the
perspective of both patients with SqCLC and adenocarcinoma regarding the access to information useful to better
cope their disease and to identify new resources that can help patients with SqCLC and their relationship with the
clinicians. In the same group of patients, we have analyzed the smoking habit and their perception about stigma.
Current treatment for advanced SqCLC
Chemotherapy
The recommended treatment in first line for metastatic or recurrent SqCLC is still chemotherapy in many European
countries, even if some changes will occur in the therapeutic algorithm with the introduction of immunotherapy
(see below). Patients with good PS 0–1 are candidates to platinum-based doublets combined with third-generation
agents. Patients with PS 2 and age <70 or PS 0–2 and age >70 are candidate to carboplatin-based chemotherapy
or single agent chemotherapy. Treatment for patients with PS 3–4 is best supportive care (BSC) [14]. Two meta-
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analyses showed benefits of chemotherapy versus BSC in terms of reduction of death risk, median survival and
quality of live irrespective of age, sex, histology and PS [15,16]. In 2004, a meta-analysis reported the survival
benefit of two-agent over one-agent chemotherapy regimens and did not show a survival benefit of three-agent
over two-agent regimens [17]. Another meta-analysis published in 2006 revealed a statistically significant reduction
(equal to 22%) in the risk of death at 1 year for platinum over nonplatinum combinations, without an increase
of toxicity. Ardizzoni et al. carried out a further meta-analysis looking at response by histological type in nine
trials involving 2968 patients: although the cisplatin-based chemotherapy was superior to the carboplatin-based
for nonsquamous cell carcinoma, both treatments were demonstrated to be equally effective for SqCLC [18].
Differences in terms of overall survival (OS) were not showed when six cycles of chemotherapy were compared
with four cycles, although a longer progression-free survival (PFS) coupled with significantly higher toxicity was
reported in patients receiving the highest number of cycles [19]. In 2008, a prospective Phase III study described for
the first time in patients with NSCLC a survival difference based on histologic type. In particular, the combination
of cisplatin/pemetrexed, compared with cisplatin/gemcitabine, demonstrated a statically significant increase of OS
for patients with adenocarcinoma but not for patients with SqCLC, in which cisplatin/gemcitabine improved
OS [20]. Recently, the association of carboplatin/nabpaclitaxel, a microtubular inhibitor conjugated with albumin,
was compared with carboplatin/paclitaxel in advanced NSCLC patients [21]. The experimental arm pointed out
a significant improvement in response rate (RR) of SqCLC (41 vs 24%; p < 0.001). This improvement was
associated with a modest, but statistically nonsignificant improvement in PFS and OS. Based on these results,
this combination was approved for the management of advanced NSCLC patients and is preferentially considered
in SqCLC. EGFR amplification occurs in 7–10% of SqCLC tumors, overexpression of the EGFR protein is
more common in SqCLC than in nonsquamous NSCLC but incidence of activating EGFR mutations is low
in SqCLC [22]. Necitumumab is an IgG1 monoclonal antibody against EGFR. The Phase III trial (SQUIRE)
evaluated cisplatin (CDDP)/gemcitabine plus necitumumab versus CDDP/gemcitabine in 1903 patients with
untreated advanced SqCLC (Table 1) [23]. The experimental arm produced a significant improvement for OS
(11.5 vs 9.9; HR: 0.84; 95% CI: 0.74–0.96; p = 0.01) and PFS, with a 1-year survival equal to 48% in the
experimental arm versus 43% in the control arm. This improvement was more pronounced in the patient group
with EGFR-expressing tumor. Based on these outcomes, necitumumab in combination with cisplatin/gemcitabine
was approved by the US FDA as first-line treatment of patients with metastatic SqCLC and by the EMA for
advanced EGFR-expressing SqCLC.
Maintenance therapy
Maintenance treatment is used to prolong the effect of first-line chemotherapy. Several studies, which included
SqCLC patients, have examined maintenance treatment in patients with advanced NSCLC without progression
after first line. Switch maintenance with docetaxel after treatment with carboplatin/gemcitabine compared with
BSC followed by docetaxel at progression showed a significant PFS benefit (5.7 vs 2.7; p = 0.0001) and a trend an
OS benefit (12.3 vs 9.7; p = 0.09) [24]. The study, that evaluated gemcitabine plus BSC versus BSC alone following
cisplatin/gemcitabine treatment, demonstrated a significant improvement in TTP (6.6 vs 5.0; p < 0.001) and
a nonsignificant improvement in OS (13.0 vs 11.0; p = 0.195) [25]. The IUNO study, that evaluated erlotinib
maintenance versus erlotinib administered at disease progression in patients with advanced NSCLC without EGFR
activating mutations, did not showed benefits in terms of OS (9.5 vs 9.7; HR: 1.02; p = 0.82) or PFS (13 vs
12 weeks; HR: 0.94; p = 0.48) [26]. Otherwise, the SATURN study, that evaluated erlotinib maintenance versus
placebo in patients with advanced NSCLC, showed significant improvements in PFS (12.3 vs 11.1 weeks; HR:
0.71; p < 0.0001) and OS (12.0 vs 11.0; HR: 0.81; p = 0.0088), with OS benefits also observed in the SqCLC
subgroup of patients who had stable disease after first-line chemotherapy (n = 190; HR: 0.67; 95% CI: 0.48–0.92;
p = 0.0116) [27].
Immunotherapy
Lung cancer has been historically considered poorly immunogenic, with no established benefit from cytokine
modulation or vaccines. In the recent years, immunotherapies have changed the treatment strategy of some types of
tumor including NSCLC, in particular with the efficacy of immune checkpoint inhibitors [28]. Immune checkpoints
are crucial for maintaining self-tolerance and modulating immune responses. It is now clear that tumors choose
immune checkpoint pathways as a major mechanism of immune resistance. The treatment by immune checkpoint
inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)
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Table 1. Available new agents for the treatment of squamous cell lung cancer.
Study Agent Study (year) Type of study Line of
treatment
Schedule Findings







Nivolumab 3 mg/kg every
14 days versus docetaxel
75 mg/mq every 21 days
Median OS: 9.2 versus 6.0 mo
(HR: 0.59; 95% CI: 0.44–0.79;
p  0.001)
Median PFS: 3.5 versus 2.8 mo
(0.62; 95% CI: 0.47–0.81;
p  0.001)
ORR (20% [95% CI: 14–28] vs
9% [95% CI: 5–15]; p = 0.008)
KEYNOTE010 Pembrolizumab Herbst et al.
(2016)




every 21 days versus
pembrolizumab 10 mg/kg
every 21 days versus docetaxel
75 mg/mq every 21 days
ORR: 19.4%
Median OS: 10.4 versus 12.7
versus 8.5 mo
Median PFS: 3.9 versus 4.0
versus 4.0 mo









Pembrolizumab 200 mg every
21 days versus investigator’s
choice platinum-based
chemotherapy
Median PFS 10.3 versus
6.0 mo (HR: 0.50; 95%
CI: 0.37–0.68; p  0.001)
OS at 6 mo: 80.2 versus 72.4%
(HR: 0.60; 95% CI: 0.41–0.89;
p = 0.005)
RR: 44.8 versus 27.8%





Second line Atezolizumab 1200 mg versus
docetaxel 75 mg/mq every
21 days
ITT population: median
OS: 13.8 versus 9.6 mo
(HR: 0.73; 95% CI: 0.62–0.87; p
= 0.003)
SqCLC median OS (HR: 0.73;
95% CI: 0.59–0.96) versus
nonsquamous (HR: 0.73; 95%
CI: 0.60–0.89)








days 1–8 plus cisplatin
75 mg/mq day 1 every 21 days
plus necitumumab 800 mg
days 1–8 versus gemcitabine
1250 mg/mq days 1–8 plus
cisplatin 75 mg/mq day 1
every 21 days
Median OS: 11.5 versus
9.9 mo (HR: 0.84; 95%
CI: 10.4–12.6; p = 0.01)









10 mg/kg every 21 days versus
docetaxel 75 mg/mq every
21 days
Median OS: 10.5 versus
9.1 mo (HR: 0.86; 95%
CI: 0.75–0.98; p = 0.023)
Median PFS: 4.5 versus 3.0 mo
(HR: 0.76, 0.68–0.86;
p  0.0001)







Afatinib (40 mg daily) or
erlotinib (150 mg daily) until
disease progression
Median OS: 7.9 versus 6.8 mo
(HR: 0.81; 95% CI: 0.69–0.95;
p = 0.0427)
Median PFS: 2.6 versus 1.9 mo
(HR: 0.81; 95% CI: 0.69–0.96;
p = 0.0103)
HR: Hazard ratio; mo: Month; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; RR: Response rate; SqCLC: Squamous cell lung cancer.
and programmed death-ligand 1 (PD-L1) pathways has led to significant clinical benefit either as monotherapy or
in combination therapy. CTLA-4, the first immune checkpoint receptor to be targeted, is a CD28 homolog that is
expressed exclusively on T cells. CTLA-4 leads to downregulation of T-cell responses through several mechanisms,
including inhibiting IL-2 production and preventing cell cycle progression thereby acting as a negative regulator
of T-cell response [29]. The role of PD-1 is limiting the activity of T cells in peripheral tissues at the time of an
inflammatory response to infection and to limit autoimmunity [30]. PD-1 expression is induced by T-cells activation
(in particular activated T cells, B cells and natural killer cells). PD-L1 is expressed across a range of tumors, including
NSCLC. The PD-1/PD-L1 interaction inhibits T-cell response, induces apoptosis of tumor-specific T cells and
promotes differentiation of CD4 T cells into Tregs and tumor cell resistance. Although PD-1 antibodies target the
PD-1 receptor on activated immune cells, PD-L1 inhibitors block the interaction between PD-L1 and PD-1 and
the interaction between PD-L1 and B7.1 (an inhibitory receptor on T cells) (Figure 1).
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Figure 1. Immune checkpoint blockade.
The most critical issue in the field of cancer immunotherapy is whether biomarkers can allow oncologists to better
identify patients most likely to respond to these new therapeutic options. It is crucial find ‘enrichment factors’ that
can identify responder patients and understand the mechanism of primary and acquired resistance. Unfortunately,
current available data are still conflicting. One of the most analyzed factor is PD-L1 that has been evaluated in
prospective and retrospective studies. In SqCLC patients, trial CheckMate 017 compared with CheckMate 057
has failed to demonstrate that PD-L1 plays a predictive role in terms of OS and PFS. These findings confirm
the differences in the microenvironment between SqCLC versus nonsquamous tumors and the need of define the
different role of biomarkers in these two histotypes.
Recent data suggest that tumor mutational burden (TMB), representing the total number of mutations per
megabase of genome examined, plays a key role for the response to immunotherapy. In 2017, Chalmers et al.
evaluated 100,000 human cancer genome and revealed that lung cancer has a high TMB with approximately 7.5
mutations/megabase compared with other cancer types, such as pediatric tumors or acute leukemia [31]. These results
confirm that patients with high TMB better respond to immunotherapy. Furthermore, in 2016, Campbell et al.
examined exome sequences and copy number profiles of 660 adenocarcinoma and 484 lung SqCLC tumors in order
to identify similarities and differences in lung carcinogenesis and new therapeutic strategies. This study showed that
recurrent alterations in SqCLC were more similar to those of other squamous carcinomas than to alterations in lung
adenocarcinoma. Particularly, in SqCLC new significantly mutated genes and new amplification peaks included
RASA1 and MIR205. Regarding neoantigens, 47% of adenocarcinoma (ADC) and 53% of SqCLC tumors had at
least five predicted neoepitopes [32].
Pembrolizumab in first-line treatment
The randomized, Phase III trial (KEYNOTE 024) compared pembrolizumab with investigator’s choice of platinum-
based chemotherapy in patients with metastatic treatment-naive NSCLC and with a PD-L1 tumor proportion
score of 50% or greater [33]. In this study, 154 patients were randomized to pembrolizumab and 151 received the
investigator’s choice of platinum-based chemotherapy. The results revealed that the 6-month OS was 80.2% with
pembrolizumab versus 72.4% with chemotherapy (HR: 0.60; 95% CI: 0.41–0.89; p = 0.005). In addition, the me-
dian PFS was 10.3 versus 6 (HR: 0.50; 95% CI: 0.37–0.68; p < 0.001) and ORR was 44.8% with pembrolizumab
versus 27.8% with chemotherapy. The median duration of the response was not reached with pembrolizumab (1.9–
14.5 months) versus 6.3 (2.1–12.6 months) with chemotherapy. The benefit of pembrolizumab respect to PFS was
evident in all subgroups. In particular, in the subgroup of patients with SqCLC, the HR for disease progression or
death was 0.35 (0.17–0.71). Based on these outcomes, pembrolizumab was approved for the treatment of patients
with metastatic treatment-naive NSCLC whose tumors express PD-L1 on at least 50% of tumor cells.
Second-line treatment for advanced SqCLC
Patients clinically or radiologically progressing after first-line chemotherapy and with PS 0–2 should be offered
second-line therapy. Combination chemotherapy regimens failed to show any OS benefit over single-agent treat-
ments [34]. The latest ESMO 2016 guidelines has recommended as therapeutic opportunities for advanced SqCLC
patients with PS 0–2: nivolumab, pembrolizumab, docetaxel, docetaxel plus ramucirumab, erlotinib and afatinib.
In the USA, NCCN guidelines state nivolumab, pembrolizumab and atezolizumab as the preferred treatments for
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advanced SqCLC and PS 0–2 based on the improved OS, longer duration of response and fewer adverse events
compared with chemotherapy. Patients with PS 3–4 should be treated with BSC.
Nivolumab, pembrolizumab & atezolizumab
Nivolumab was the first PD-1 immune checkpoint inhibitor to be approved in advanced SqCLC after previous
platinum-based chemotherapy (Table 1) [35]. The randomized, Phase III trial CheckMate 017 compared nivolumab
(3 mg/kq every 14 days) versus docetaxel (75 mg/mq every 21 days) as second-line therapy in 272 patients
with advanced or metastatic SqCLC already treated with platinum-based chemotherapy. The experimental arm
experienced a 41% OS advantage over the docetaxel arm (9.2 vs 6.0; HR: 0.59; 95% CI: 0.44–0.79; p = 0.00025),
significant improvements in PFS (3.5 vs 2.8; HR: 0.62; 95% CI: 0.47–0.81; p < 0.001), higher RR (20 vs 9%;
p = 0.008) and a marked increase of 1-year survival (42 vs 24%). PD-L1 expression levels (1, 5 or 10% cutoffs) did
not appear prognostic and predictive in terms of OS and PFS. The Phase II/III KEYNOTE-010 trial showed that
in 1034 patients with advanced PD-L1-expressing NSCLC after first-line chemotherapy, pembrolizumab 2 and
10 mg/kg increased OS compared with docetaxel in patients with both TPS ≥50% (2 mg/kg: 14.9 vs 8.2; HR:
0.54; 95% CI: 0.38–0.77; p = 0.0002 and 10 mg/kg: 17.3 vs 8.2; HR: 0.50; 95% CI: 0.36–0.70; p < 0.0001)
and TPS ≥1% (2 mg/kg: 10.4 vs 8.5; HR: 0.71; 95% CI: 0.58–0.88; p = 0.0008 and 10 mg/kg: 12.7 vs 8.5; HR:
0.61; 95% CI: 0.49–0.75; p < 0.0001) (Table 1) [36]. Atezolizumab is a humanized IgG1 monoclonal antibody
targeting PD-L1. The randomized, Phase III trial (OAK study) evaluated atezolizumab versus docetaxel alone in
1225 patients with advanced NSCLC who had progressed during or after platinum-based chemotherapy. Prolonged
OS was observed in the atezolizumab arm, regardless of PD-L1 expression levels on tumor cells (TC) or immune-
infiltrating tumor cells (IC). OS was only slightly improved in patients with SqCLC receiving atezolizumab versus
docetaxel (8.9 vs 7.7; HR: 0.73; 95% CI: 0.54–0.98; p = 0.038); however, there were fewer patients in the
squamous group when compared with the nonsquamous group (222 vs 628) (Table 1) [37].
Antibody-targeting VEGF
Angiogenesis plays a key role in the process of tumor growth, cancer dissemination and survival of tumor cells [38].
Therefore, targeting the angiogenesis pathway has been identified as an attractive opportunity. One of the best
characterized groups of protein factors includes VEGF and additional signaling molecules and pathways contribute
to aberrant blood vessel formation. Bevacizumab, a recombinant humanized monoclonal antibody against VEGF,
was approved for the first-line treatment of advanced NSCLC with nonsquamous cell histology in combination
with carboplatin and paclitaxel [39]. Despite the efficacy demonstrated by bevacizumab in Phase II and III trials
in patients with all NSCLC, clinically significant bleeding events, including major hemoptysis, delayed further
evaluation of bevacizumab in patients with SqCLC.
Ramucirumab is a fully human monoclonal antibody that targets VEGFR2, preventing binding of all VEGF
ligands. The combination of ramucirumab with docetaxel is a therapeutic option for patients with advanced NSCLC
progressed after first-line treatment (Table 1) [40]. The registration study compared docetaxel plus ramucirumab
or placebo in 1253 patients (25% with SqCLC) who had progressed during or after first-line chemotherapy. In
overall population, experimental arm significantly improved median OS (10.5 vs 9.1; HR: 0.86; 95% CI: 0.75–
0.98; p = 0.023) and PFS (HR: 0.76; p < 0.0001) and similar, but nonsignificant OS benefits were observed
in the SqCLC subgroup (n = 328; 9.5 vs 8.2; HR: 0.88; 95% CI: 0.69–1.13). In terms of safety, no significant
class effects were observed even if an increase of hematological toxicity was described in the combination arm.
Nintedanib is an oral angiokinase inhibitor of VEGFR 1–3, FGFR 1–3 and PDGFR-α and -β. The registration
study compared docetaxel versus docetaxel/nintedanib in 1314 NSCLC patients, 42% of whom were SqCLC [41].
PFS was significantly longer in the docetaxel plus nintedanib group compared with docetaxel alone (3.4 vs 2.7;
HR: 0.79; 95% CI: 0.68–0.92; p = 0.0019). Similar results were noted both in adenocarcinoma and SqCLC
patients. However, OS was significantly longer only in the subgroup of patients with adenocarcinoma, and the
greatest advantage was observed in those who had progressed within 9 months after first-line chemotherapy (OS:
10.9 vs 7.9; HR: 0.75; 95% CI: 0.60–0.92; p = 0.0073). Based on this trial, FDA approved the combination of
nintedanib plus docetaxel as second-line treatment for patients with advanced adenocarcinoma.
EGFR-targeted therapies
Erlotinib, a first generation EGFR TKIs, has demonstrated survival benefit of 2 months versus BSC in unselected
patients with advanced NSCLC with progressive disease after one or two lines of treatment and not candidate
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for chemotherapy [42]. Different Phase III studies have also investigated the role of EGFR TKIs in comparison
with docetaxel for the second- or third-line treatment of unselected for EGFR mutations NSCLC patient. The
randomized, Phase III trial (TAILOR) comparing docetaxel versus erlotinib in patients with metastatic NSCLC
and EGFR wild-type tumors (n = 222), demonstrated the superiority of docetaxel over erlotinib in terms of PFS
and OS (8.2 vs 5.4; HR: 0.78; 95% CI: 0.51–1.05; p = 0.10) [43]. The randomized, Phase III trial (DELTA),
that evaluated erlotinib versus docetaxel as second- or third-line therapy, demonstrated superior PFS but not OS
for docetaxel treatment in wild-type (WT) EGFR [44]. In 2016, FDA modified the indication for erlotinib for
treatment of NSCLC to limit use to patients whose tumors have specific EGFR mutations.
Most recently, the Phase III trial Lux-Lung 8 evaluated afatinib versus erlotinib in 795 patients with SqCLC
progressing after four cycles of platinum-based chemotherapy. A modest, but significant improvement was observed
for afatinib in terms of PFS (HR: 0.81; p = 0.0103) and OS (7.9 vs 6.8; HR: 0.81; 95% CI: 0.69–0.95;
p = 0.0077) (Table 1) [45]. In conclusion, according to ESMO guideline, erlotinib still represents a potential
second-line treatment option in pretreated patients with unknown or WT EGFR status and preferably in patients
not suitable for chemotherapy, with, however, limited efficacy in WT EGFR patients compared with chemotherapy.
Emerging agents
SqCLC displays a somatic mutation rate comparable to that of patients with small cell lung cancer or other
smoking-related cancers, different from what described in lung adenocarcinoma in which cancers from nonsmokers
harbor one-fifth to one-sixth the genomic alterations of a smoker’s cancer [46]. SqCLC is strongly associated to
smoking, however, also occurs in a small number of never or light smokers. Several etiologic factors have been
proposed to explain the development of lung cancer in never smokers. In recent years, there have been large
technological advances in particular with the development of next-generation sequencing (NGS) [47]. NGS can
sequence complete genomes, exomes and transcriptomes and identify novel chromosomal rearrangements and copy
number alterations. International guidelines strongly advise molecular profiling to identify driver mutations to
ensure that patients receive the most appropriate treatment. Based on these perspectives, smokers or light smokers
with SqCLC should be characterized by NGS in order to evaluate molecular profile with important clinical
implications.
In 2012, the Cancer Genome Atlas profiled 178 untreated SqCLC tumor specimens for genomic alterations
by whole exome sequencing and mRNA sequencing. The study found statistically recurrent mutations in 18
genes including: TP53, NFE2L2/KEAP1 in 34%, squamous differentiation genes in 44%, PI3K/AKT in 47%
and CDKN2A/RB1 in 72% of tumors with at least one potentially therapeutic target in each of the analyzed
specimens [48]. The FGF and FGFR pathway is considered one of the most promising druggable targets in SqCLC.
FGFR amplification is found in approximately 10–20% of SqCLC with subsequent activation of PI3K/AKT and
RAS/MAPK pathways that stimulate growth and angiogenesis, while mutations are in approximately 0–8% of
cases [49]. Several FGFR inhibitors have been evaluated, including dovitinib and AZD4547. In patients with SqCLC,
a Phase II trial evaluated dovitinib, a multikinase inhibitor of FGFR 1–3, VEGFR 1–3, PDGFR-β, c-KIT and
FLT3, and showed limited antitumor activity and side effects including gastrointestinal toxicity (nausea, diarrhea
and anorexia), skin rash and fatigue [50]. AZD4547, a selective inhibitor of FGFR 1–3 and VEGFR2, remains
largely under investigation and early phase trials have reported mixed results in terms of efficacy [51]. The PI3KCA
pathway is an intracellular signaling involved in the development and progression of advanced lung cancer [48]. The
PI3KCA gene amplification and mutations, which are both found predominantly in SqCLC, occur in a range of
35 and 6.5%, respectively [52]. Nowadays, various agents targeting this pathway are in development including dual
PI3K/mTOR inhibitors, isoform-specific and pan-isoform PI3KCA inhibitors. DDR2 is a receptor expressed in
normal cells and its binding with ligand promotes migration, differentiation, proliferation and survival [53]. DDR2
mutations occur in approximately 1–4% of SqCLC patients and dasatinib, a multityrosine kinase inhibitor that
targets BCR-ABL, Src family, c-KIT and PDGFR-β, has emerged as a new therapeutic option. A Phase II trial
evaluated the RR of dasatinib at the dose of 140 mg in patients with SqCLC previously treated with first-line
chemotherapy. This study showed that dasatinib administered at 140 mg/day was associated with excess adverse
events and consequently not recommended. Further studies to identify patients likely to benefit from dasatinib and
to manage dasatinib-related toxicities are needed [54].
Other targets with active agents that are under investigation include PDGFR, AKT pathway and MET amplifi-
cation that has been reported in 6–10% of SqCLC but, until now, several trials have failed to show any results in
SqCLC subpopulation. The biomarker-driven Lung Cancer Master Protocol (S1400) (NCT02154490) is Phase
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II/III study, using a multidrug, targeted screening approach to match patients with substudies testing investigational
new treatments based on their unique tumor profiles evaluated by NGS [55]. Patients are then randomized to one of
several substudies, each evaluating standard of care versus an experimental targeted therapy, based on identification
of candidate predictive biomarkers. Lung Cancer Master Protocol could change the way new drugs in lung cancer
are developed.
In the last few years, immunotherapy has changed therapeutic landscape for patients with SqCLC; in order
to maximize the benefit of this new approach, the combinations of immune checkpoint inhibitors with other
treatment options such as chemotherapy, targeted therapy, radiotherapy and other immunotherapeutic agents are
being evaluated. These combinations can obtain higher RRs, more durable responses, and may expand the number
of patients treating with benefit. The association of immune checkpoint inhibitors is more effective, but also more
toxic than single agent. The efficacy of chemotherapy combined with immunotherapy depends on the drug, and
the relative timing of administration. A randomized, Phase II study evaluated the addition of pembrolizumab
to carboplatin/pemetrexed for advanced nonsquamous NSCLC, with an ORR of 55% for experimental arm
compared with 29% for chemotherapy [56]. Based on this trial, the FDA approved pembrolizumab in combination
with pemetrexed and carboplatin for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of
PD-L1 expression.
An ongoing randomized, Phase III study is evaluating carboplatin/paclitaxel with or without pembrolizumab in
patients with SqCLC and results are pending (NCT02775435). EGFR TKIs have significantly improved clinical
outcomes compared with chemotherapy in NSCLC patients with sensitizing EGFR mutation. Almost all patients
treated with EGFR TKIs develop acquired resistance during variable time. Preclinical studies have showed that
activated mutations increases susceptibility of the lung tumors to PD-1 blockade, suggesting that the combination
of PD-1 inhibitors with EGFR TKIs may be a promising therapeutic strategy. The study CheckMate 012 evaluated
erlotinib plus nivolumab in 21 EGFR-mutated NSCLC patients (20 patients pretreated with erlotinib and 1 EGFR
TKI naive) [57]. The ORR was 19%, PFS at 24 weeks was 51% and OS at 18 months was 64%, but the grade
3 toxicities were reported in 19% of patients. The combination of osimertinib plus durvalumab in pretreated or
chemo-naive NSCLC patients showed encouraging clinical activity; however, this combination was associated with
high incidence of interstitial lung disease (38%), leading to termination of further enrollment [58]. Considering
the high incidence of treatment-related toxicities associated with combination of EGFR TKI and immunotherapy,
further development of this approach remains controversial. Radiotherapy is used for local tumor control and
palliation of symptoms. The abscopal effect, which is the regression of nonirradiated lesions after the irradiation of
an index lesion, is an important observation and reflect secondary activation of antitumor immunity [59].
Coping with diagnosis of SqCLC
There has been an important statistical increase in oncological diseases in recent decades, and the problem of
diagnostic information and communication between physician and patient has been at the center of an intense
debate in the legal, ethical and psychological fields.
Telling or not telling the ‘truth’ to the cancer patient is an old, still current issue in Italy. On the other hand,
the way in which an empathic relationship with the patient is established is certainly an integral part of the
attitudes of the physician, certainly not less than the appropriate choice of the chemotherapy protocol and the
quality of the supportive therapies ‘logistical-welfare organization’. In oncology, the strong burden of anxiety that
tumor illnesses evoke, the persistence of treatments that have important side effects and the increase in survival
require a continuity of communication and relationship between physician and patient that provides the person
with adequate and personalized information on his/her disease. The condition of patients with advanced SqCLC
still remains challenging for several reasons; they too would need to receive specific information to improve their
understanding about treatment options, about the impact of the disease and the drugs in the daily life and about the
way to face this condition. Although a lot of information is provided on adenocarcinoma and related issues, there
are not so many resources dedicated to SqCLC and only recently has information focused on this NSCLC subtype
become more available. About 3 years ago, a survey carried out worldwide and highlighted that there is still a severe
lack of patient education and awareness of SqCLC, perhaps due to the strong association between this disease and
smoking cigarette and the persistent stigma around it. This gap needed to be addressed and in late 2014 a pharma
company initiated the SqCLC consortium with the aim to assess the unmet educational needs around this subtype of
lung cancer and developing appropriate resources. It has brought together an international, multidisciplinary group
of highly experienced clinicians, nurses and patient advocates, who have developed a series of educational initiatives
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and among the others, a patient booklet that directly addresses patients’ and caregivers’ need for information about
SqCLC; it has been intentionally prepared as a printed booklet and has been made available from a range of
sources, including patient Advocacy Groups, congress booths and symposia and in PDF format from the IASLC
and Advocacy Group (www.iaslc.org/patient-resources/resources). The booklet titled ‘Living with Squamous Cell
Lung Cancer’, containing 50 most frequent questions (with responses) and covering all aspects across the SqCLC
patient journey was launched during the World Conference on Lung Cancer in December 2016 in Vienna and it
is currently distributed in Europe and USA with the help of the local advocacy groups. In this scenario, advocacy
groups like WALCE, Lung Cancer Europe, Bonnie J Addario Lung Foundation (ALCF) and LUNGevity that have
actively contributed to the development and dissemination of the booklet may play a key role in order to help
patients to increase the understanding of their disease and to foster patients to become more active participants in
their decision making and care, because changes may happen whether patients understand why action is necessary.
Italian monocentric survey: patients with advanced SqCLC & their perception about available
information for their disease comparing to patients with adenocarcinoma
Based on the above-mentioned evidences, we performed a prospective monocentric survey with the aim to investigate
the possibility of patients with SqCLC to obtain useful information about their disease compared with patients
with adenocarcinoma. Furthermore, we evaluated smoking habit of patients and their perception of stigma and
blame. Patients with SqCLC and adenocarcinoma (comparing group) were recruited between April 2017 and
May 2017 at a single institution (Thoracic Oncology Division, ‘San Luigi Gonzaga Hospital’, Orbassano, Turin,
Italy). They have been assessed for their smoking habit and the level of useful information that has been obtained
with available resources. Patients were evaluated before starting treatment with anonymous 20 questions, self-
administered and compiled only once during the study. Main questions are listed in Box 1. The entire project
was designed and supported by WALCE and approved by local ethical committee. 50 consecutive patients were
enrolled in this study. Clinical and social characteristics are reported in Table 2. Totally, 15 patients (30%) have
stopped smoking after diagnosis (36% SqCLCs and 25% adenocarcinomas), 14 (28%) before diagnosis (69%
SqCLCs and 51% adenocarcinomas), 10 (20%) have continued smoking after diagnosis (23% SqCLCs and 16%
adenocarcinomas) and 11 (22%) have never smoked (8% SqCLCs and 33% adenocarcinomas). Totally, 21 patients
(42%) have decided to stop by themselves, 8 (16%) have been helped by family and physicians. Totally, 31 patients
(62%) have thought that their disease was correlated to smoking habit and most of them (40%) have felt guilty,
26 (52%), 32 (64%) and 27 (54%) patients have denied being judged by their family, physicians and society,
respectively. Regarding their disease, 27 (54%) patients have asked to their physicians if other treatments, beyond
chemotherapy, were available and most of them were interested about immunotherapy (in particular eight patients
with adenocarcinomas and three patients with SqCLCs) and targeted therapy (in particular seven patients with
adenocarcinomas and one patient with SqCLC). Totally, 68% of SqCLC and 61% of adenocarcinoma patients have
answered that available resources are enough to get information about their disease and the majority of them referred
to their physicians they have used booklets or websites and blog/forum, as main sources. In squamous subgroup,
65% would need to have a dedicated materials for their histotype (e.g., a booklet) and 64% of adenocarcinoma
patients have answered not to know about this possibility. None of the patients asked for help from advocacy group.
Totally, 52% of patients think not to have specific ‘need’, but for 18 patients (36%) the most important need is
clinical and 6 patients (12%) needed psychological support. This survey, with the limitation of the small sample
of patients enrolled, has not shown great differences between patients with SqCLC and adenocarcinoma, at least
in the items examined. Regarding smoking status after the diagnosis of lung cancer, it is important to highlight
that patients often do not stop smoking, because they wrongly believe that is too late and not useful for the disease
and treatments. Furthermore smoking may help patients to deal with the anxiety for their condition. Regarding
the first objective, patients with SqCLC, as adenocarcinoma patients, have answered that available resources for
their disease are sufficient and they have considered their physicians as main resource. These data confirm the
importance of the relationship between patients and their clinicians. Patients trust in their physicians to provide
the most reliable information, and they do not need to consider other sources in order to collect it. It could
be intriguing to consider if in a multicentric observation or in other countries the results could be similar to
this study. Looking at the data, patients with adenocarcinoma, comparing with SqCLC patients, have requested
more information about immunotherapy. This is quite unexpected considering that immunotherapy has been first
approved for the squamous setting, but it may be explained by the fact that patients with adenocarcinoma tend
to make more questions about their disease and new therapeutic options. Results about secondary objective have
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Primary school 19 (38%)
Secondary school 13 (26%)





Unemployed for health reason 3 (6%)




Squamous cell carcinoma 22 (44%)
Adenocarcinoma 28 (56%)
Smoking status
Never smoker 11 (22%)
Former smoker (several years/months before diagnosis) 11 (22%)
Former smoker (shortly before diagnosis) 3 (6%)
Former smoker (after diagnosis) 15 (30%)
Smoker 10 (20%)
evidenced that the majority of patients were former smokers and the percentage of never smokers was greater in
the adenocarcinoma subgroup than in the squamous according to the known epidemiological data. Results about
guilty and stigma were similar in the two subgroups. This survey has also highlighted that patients have not looked
for help from advocacy groups and this can be due to cultural habit, but also to the fact that advocacy groups
specifically focusing lung cancer are not so frequent as those for other malignancies (i.e., breast cancer or colorectal
cancer), at least in Europe. This survey can offer a partial vision about the binding between SqCLC patients and
resources for their disease, but further evaluations are needed to have more details.
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 Age (in years)













 Unemployed for health reasons





 Former smoker (suspended several months/years before diagnosis of lung cancer)
 Former smoker (suspended shortly before diagnosis of lung cancer)
 Former smoker (suspended after diagnosis of lung cancer)
 Still smoker
 If you stopped smoking after diagnosis, who helped/encouraged you?
 Family
 Physicians
 Family and physicians
 Friends
 No one, only for my own decision




 If you have answered yes to the previous question, have you ever felt guilty for having smoked?
 Yes
 No
 As a smoker or former smoker, at the moment of diagnosis have you been judged by your family and/or friends?
 Yes
 No




 Have you ever felt judged by public information (TV, newspapers, social)?
 Yes
 No
 Have you ever asked to your physician or looked for information about therapies beyond chemotherapy?
 Yes
 No
 If you have answered yes to previous question, which alternative therapies have you thought?
 Tablets (targeted therapy)
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 Immunotherapy
Other
 Do you think that booklets, website and newspapers are enough to get information about your disease?
 Yes
 No




 Blog or forum




 If you have answered yes to previous question, on which histology (type) of tumor have you found more
information using available tools?
 Squamous cell lung cancer
 Adenocarcinoma
 Both
 Do you think that it might be useful to have scientific material dedicated only to squamous subtype?
 Yes
 No
 I do not know
 At the time of diagnosis, have you looked for patient’s association to have support and information?
 Yes
 No




Conclusion & future perspective
During the last 12 months, new therapeutic options have been introduced in the therapeutic algorithm of SqCLC.
Immune checkpoint inhibitors have changed the therapeutic strategy for SqCLC and other options were developed
in second line, including ramucirumab and afatinib. However, the lack of biomarkers, that predict which patients
could better respond and benefit from each therapy, remains an unresolved issue that future studies could resolved.
The situation is still evolving and it is important for patients affected by SqCLC to be aware of this change. For them,
it is crucial to refer to reliable sources as their oncologists, and to scientific organizations like IASLC (www.iaslc.
org/about-lung-cancer) or advocacy groups like WALCE (www.womenagainstlungcancer.eu/wp-content/uploads/
2011/08/living with sqclc - a guide for patients nov2016 0.pdf ).
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